The aim of the study is to develop and implement robust analytical protocols for first-void urine sample preparation and antibody assays to monitor vaccine induced immunity against HPV (Human Papillomavirus).
Participants of the HPV V503-004 study (Phase III Clinical trial vaccinating (young) adult women in Antwerp, EudraCT NUMBER: 2015-005093-38) will be asked if they are willing to provide two additional urine samples at day 1 and month 7 for biomedical research. Furthermore, they will be contacted again at approximately 3.5 years and asked if they are willing to provide an additional urine sample and a serum sample. At 3.5 years, they will also be asked to fill in a brief questionnaire. The collected urine will be used for the development and optimization of robust analytical protocols for sample preparation and antibody assays.
Study Type
OBSERVATIONAL
Enrollment
63
Collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) during visit at the Centre for the Evaluation of Vaccination.
Blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccination.
university of Antwerp - centre for the evaluation of vaccination
Wilrijk, Antwerp, Belgium
Concentration of HPV specific IgG (Immunoglobulin G) in FV urine.
To detect HPV specific IgG concentrations (ratio HPV specific IgG/total human IgG), in first-void urine from 63 women to monitor the immune response before and after vaccination with a prophylactic HPV vaccine (Gardasil9).
Time frame: Within 6 months after study completion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.